Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on February 26, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Q4 and full year 2025 financial results announced Feb 26, 2026: full figures in Exhibit 99.1 press release.
BIOCRYST PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4 and full year 2025 financial results announced Feb 26, 2026: full figures in Exhibit 99.1 press release
- Filing also covers "recent corporate developments," suggesting potential pipeline or business updates beyond routine earnings
Item 7.01 · Regulation FD Disclosure
- Reg FD disclosure references Exhibit 99.1: contains the material information investors should review directly
- Standard legal language limiting liability; actual substance in attached exhibit, not this item text
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOCRYST PHARMACEUTICALS INC 8-K filings
Get the next BCRX 8-K as it lands
Follow BCRX for push alerts, or ask the research agent what this filing means.